Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) Leases (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Leases for 5 consecutive years, with $2.5 million as the latest value for Q1 2026.

  • For Q1 2026, Leases rose 546.39% year-over-year to $2.5 million; the TTM value through Mar 2026 reached $2.5 million, up 546.39%, while the annual FY2025 figure was $2.6 million, 324.63% up from the prior year.
  • Leases hit $2.5 million in Q1 2026 for Phathom Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Leases topped out at $2.7 million in Q3 2025 and bottomed at $388000.0 in Q1 2025.
  • Average Leases over 5 years is $1.7 million, with a median of $1.8 million recorded in 2022.
  • Year-over-year, Leases crashed 69.3% in 2025 and then soared 546.39% in 2026.
  • Phathom Pharmaceuticals' Leases stood at $2.3 million in 2022, then plummeted by 35.51% to $1.5 million in 2023, then tumbled by 58.44% to $613000.0 in 2024, then soared by 324.63% to $2.6 million in 2025, then decreased by 3.65% to $2.5 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $2.5 million, $2.6 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.